Search research articles
Contact Us
Filters
Showing results (261-270 of 264) with videos related to
Page
of 27
Sort By:
You have reached the last page of results.
This site can display upto 264 results.
Proceedings of the National Academy of Sciences of the United States of America
|
August 27, 2005
Direct recognition by alphabeta cytolytic T cells of Hfe, a MHC class Ib molecule without antigen-presenting function
Pierre S Rohrlich, Nicolas Fazilleau, Florent Ginhoux, et al.
Plos Pathogens
|
May 19, 2011
CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitope
Sylvain Cardinaud, Gesa Consiglieri, Romain Bouziat, et al.
Diabetologia
|
April 25, 2012
Zinc transporter (ZnT)8(186-194) is an immunodominant CD8+ T cell epitope in HLA-A2+ type 1 diabetic patients
M Scotto, G Afonso, E Larger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 23, 2004
NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors
Eugene Maraskovsky, Sigrid Sjölander, Debbie P Drane, et al.
Page
of 27
Search research articles
Search
Showing results (261-270 of 264) with videos related to
Sort By:
Page
of 27
You have reached the last page of results.
This site can display upto 264 results.
Proceedings of the National Academy of Sciences of the United States of America
|
August 27, 2005
Direct recognition by alphabeta cytolytic T cells of Hfe, a MHC class Ib molecule without antigen-presenting function
Pierre S Rohrlich, Nicolas Fazilleau, Florent Ginhoux, et al.
Plos Pathogens
|
May 19, 2011
CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitope
Sylvain Cardinaud, Gesa Consiglieri, Romain Bouziat, et al.
Diabetologia
|
April 25, 2012
Zinc transporter (ZnT)8(186-194) is an immunodominant CD8+ T cell epitope in HLA-A2+ type 1 diabetic patients
M Scotto, G Afonso, E Larger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 23, 2004
NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors
Eugene Maraskovsky, Sigrid Sjölander, Debbie P Drane, et al.
Page
of 27